Included in the formulation
АТХ:G.04.C.X Other drugs for the treatment of benign prostatic hyperplasia
G.04.C.X.02 Palm Creeping Fruit
Pharmacodynamics:Inhibits aromatase and 5-α-reductase, under the influence of which testosterone biotransformiruetsya in dihydrotestosterone and estradiol, activating growth factors of fibroblasts and prostatic epithelium. Interacts with cytosolic androgen receptors of the prostate by competitive or specific binding.
Has a nonspecific anti-inflammatory and anti-exsudative effect. With narrowing of the urethra in the early stage of prostatic hyperplasia, it reduces the symptoms of urination disorders. Reduces the severity of pain and burning when urinating, reduces the urge to urinate,facilitates the emptying of the bladder.
Pharmacokinetics:Not studied.
Indications:It is used for the treatment of urinary disorders associated with benign prostatic hyperplasia. Used in the complex therapy of chronic prostatitis.
XIV.N40-N51.N40 Hyperplasia of the prostate
XIV.N40-N51.N41 Inflammatory diseases of the prostate
Contraindications:Individual intolerance.
Pregnancy and lactation:Recommendations for FDA - The drug is not intended for use in women.
Dosing and Administration:Inside at the time of ingestion of 160 mg 2 times / day or 320 mg once in the evening. With a more pronounced clinical picture of the disease, the dose doubles.
The highest daily dose: 640 mg.
The highest single dose: 320 mg.
Side effects:Digestive system: rarely - dyspeptic disorders.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:Before the appointment of the drug, it is necessary to exclude the malignant process of the prostate gland.